SCHEMBL7187033

SCHEMBL7187033

COc1c(Cl)cc(Cl)c(OC)c1C(=O)P(=O)(C(=O)c1c(C(F)(F)F)cccc1C(F)(F)F)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
LMNA P02545 3/20 0.40
GAA P10253 2/20 0.40
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 1/20 0.37
TYK2 P29597 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
HTT P42858 2/20 0.36
HPGD P15428 1/20 0.36
TMPRSS4 Q9NRS4 1/20 0.35
DRD3 P35462 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CTSS P25774 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7186868 0.92 POLB (0.38) MAPTLMNAGAARAB9AALDH1A1
SCHEMBL7182312 0.91 ALDH1A1 (0.46) MAPTLMNAGAARAB9AALDH1A1
SCHEMBL7181918 0.88 MAPT (0.43) MAPTLMNAGAARAB9AALDH1A1
SCHEMBL7735676 0.87 CTSS (0.35) MAPTLMNAGAARAB9AALDH1A1
SCHEMBL7187008 0.85 ALDH1A1 (0.45) MAPTLMNAALDH1A1KDM4EHSD17B10
SCHEMBL7181377 0.84 TYK2 (0.40) LMNAGAAKDM4ETYK2CTSS
SCHEMBL7188697 0.84 SLC6A9 (0.42) MAPTLMNAGAARAB9AALDH1A1
SCHEMBL7182471 0.83 CA12 (0.43) MAPTLMNARAB9AALDH1A1KDM4E
SCHEMBL7182765 0.83 TAS1R3 (0.45) MAPTLMNARAB9AALDH1A1KDM4E
SCHEMBL7182186 0.82 TYK2 (0.48) TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885LMNA 3241/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885LMNA 3247/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.